Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ado-trastuzumab emtansine · 1 trial · 4 indications
As soon as evaluations for each tumor assessment are completed, the Investigator should assess the patient's overall response (target plus non- target lesions) based on criteria and overall response algorithms as defined in RECIST version 1.1. Scans must be assessable for all evaluations.
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Lung cancers, HER2 mutant | EXPERIMENTAL | - |
| Cohort 2: Lung cancers, HER2 amplified | EXPERIMENTAL | - |
| Cohort 3: Colorectal cancers | EXPERIMENTAL | - |
| Cohort 4: Endometrial cancers | EXPERIMENTAL | - |
| Cohort 5: Salivary gland cancers | EXPERIMENTAL | - |
| Cohort 6: Other solid cancers | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ado-trastuzumab emtansine | DRUG | Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity. |
Inclusion Criteria: * Adults who are ≥18 years old. * Pathologically confirmed advanced solid tumor cancers * For Cohort 1, documented activating HER2 mutation in lung cancer by CLIA laboratory, specifically exon 20 insYVMA (Y772\_A775dup), insGSP (G778\_P780dup), insTGT (G776delinsVC), single base...